Alembic Pharmaceuticals Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/38nvolh4zbr11j8v0e10mubr.pdf

Key Takeaways


India Branded Business: The Core Problem

Shaunak Amin: "I can't give you exact timeframe, but like I said, it's a matter of months that we start seeing double-digit growth and beating or matching market growth."

US Generics: Volume Offsetting Price Erosion

Pranav Amin: "Increasing manufacturing footprint in the US just because of tariffs is something, in my opinion, not something that we are considering. If there was a strategy based on US government business or something that you can get at a better pricing, then we would look at a manufacturing strategy in the US. But purely for the de-risk perspective, it doesn't make sense to allocate so much capital for setting a manufacturing in the US."

API Business: A Structural Pricing Problem

Pranav Amin: "Now with this data that is getting leaked through Chinese traders, everyone knows what price you're selling it at, to which buyer. And that's really caused a lot of appeal and a lot of uncertainty in terms of our pricing."

Margins & Cost Structure


International & RoW Generics


Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
US business growthAt least 10% growth each quarter; full-year 10–15%Q2–Q4 FY26
US product launches4–5 more products in Q2; 10–15 in the rest of FY26Q2 and full-year FY26
India branded businessReturn to double-digit growth, beating or matching market growthWithin months (no exact date)
RoW generics growthClose to 10–15% growthFull-year FY26
R&D spend₹600–₹650 croresFull-year FY26
CAPEX~₹400 crores, mainly maintenance and debottleneckingFull-year FY26
Full-year ETR17–18%Full-year FY26
API business recoverySlow growth to resume after a tough couple of quarters2–3 quarters out

Key Metrics

MetricQ1 FY26
Total revenue₹1,711 cr, +10% YoY
India branded business revenue₹599 cr, +5% YoY
US generics revenue growth+13% YoY, supported by volume gains
Rest of world generics revenue growth+21% YoY
API business revenue₹261 cr, flat YoY
Gross margin (net of material cost)76.2%, improved from 74.8% in Q1 FY25
EBITDA margin before R&D25% of revenue, ₹424 cr, +23% YoY
EBITDA after R&D₹288 cr, 17% of revenue, +20% YoY
R&D expenses₹145 cr, +26% YoY; full-year guidance ₹600–650 cr
Profit before tax₹191 cr, +21% YoY
Net profit₹154 cr, +15% YoY
EPS₹7.85 per share, vs ₹6.84 in Q1 FY25
Gross debt₹1,185 cr as of June 30
Net debt₹967 cr as of June 30
US business as share of total~29% of total business
ANDAs filed in quarter2 filed; 6 approvals received; 4 products launched
US launches expected in Q2 FY264 to 5 products
US full-year growth expectation10% to 15%
RoW full-year growth expectationclose to about 10%–15% at least
Effective tax rate~19% in Q1; full-year guidance 17%–18%
CAPEX guidance for FY26~₹400 cr, primarily maintenance, replacement, debottlenecking